US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Liquidia Corporation - Common Stock (NQ:LQDA)

28.64 +0.65 (+2.32%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
From Liquidia Corporation
Via GlobeNewswire
News headline image
Decoding 5 Analyst Evaluations For Liquidia ↗
 
Via Benzinga
News headline image
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Announces $100 Million in New Financings
From Liquidia Corporation
Via GlobeNewswire
News headline image
B of A Securities Maintains Buy Rating for Liquidia: Here's What You Need To Know ↗
 
Via Benzinga
Liquidia Corp. (NASDAQ: LQDA) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
News headline image
MarketBeat Week in Review: 12/25 - 12/29
The Santa Claus rally took the S&P 500 up about 0.75%, but recession concerns linger as the full impact of the Fed's rate hikes hasn't hit the economy. 
Via MarketBeat
Topics Economy Stocks
News headline image
Liquidia: Court victory the awakening of an industry giant?
Liquidia's stock surged after an enormous court win against United Therapeutics, accompanied by analyst upgrades and insider buying. 
Via MarketBeat
Topics Intellectual Property
News headline image
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
From Liquidia Corporation
Via GlobeNewswire
News headline image
Earnings Outlook For Liquidia ↗
 
Via Benzinga
News headline image
Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today? ↗
Liquidia Corp (NASDAQ: LQDA) stock jumped after a win in a pat 
Via Benzinga
News headline image
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
United Therapeutics: A Strong Quarter But What About 2024? ↗
United Therapeutics had strong Tyvaso sales but it highlights the investor debate heading into 2024. 
Via Talk Markets
News headline image
What 5 Analyst Ratings Have To Say About Liquidia ↗
 
Via Benzinga
News headline image
Preview: Liquidia's Earnings ↗
 
Via Benzinga
News headline image
Where Liquidia Stands With Analysts ↗
 
Via Benzinga
News headline image
Toro Posts Upbeat Results, Joins Clear Channel Outdoor, Marathon Digital And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Liquidia Announces Pricing of Public Offering of Common Stock
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
From Liquidia Corporation
Via GlobeNewswire
News headline image
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
News headline image
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
From Liquidia Corporation
Via GlobeNewswire
News headline image
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
From Liquidia Corporation
Via GlobeNewswire
News headline image
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
Via Benzinga
Topics Bankruptcy
News headline image
Earnings Scheduled For August 10, 2023 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
News headline image
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
From Liquidia Corporation
Via GlobeNewswire
News headline image
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
From Liquidia Corporation
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >